- US-listed companies
- DiaMedica Therapeutics Inc.
- Income statement
DiaMedica Therapeutics Inc.DMAC
Market cap
$375.66M
P/E ratio
| 2018/12 | 2019/12 | 2020/12 | 2021/12 | 2022/12 | 2023/12 | 2024/12 | |
| Revenue | 1 | - | - | - | - | - | - |
| Research & development | 5 | 8 | 8 | 9 | 8 | 13 | 19 |
| Operating margin (%) | - | - | - | - | - | - | |
| Operating income | -7 | -12 | -13 | -14 | -14 | -21 | -27 |
| Operating expenses | 7 | 12 | 13 | 14 | 14 | 21 | 27 |
| Income before tax | -6 | -11 | -12 | -14 | -14 | -19 | -24 |
| Pretax margin (%) | -1,130.8 | - | - | - | - | - | - |
| Provision for income taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective tax rate (%) | |||||||
| Net income | -6 | -11 | -12 | -14 | -14 | -19 | -24 |
| Net income margin (%) | - | - | - | - | - | - | |
| Earnings per share | - | - | - | - | -0.52 | -0.6 | -0.6 |
| Diluted EPS | - | - | - | - | -0.52 | -0.6 | -0.6 |